Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesChemotherapy DrugsHCPCS hcpcs-j9357-valrubicin-intravesical-200mg
    Ask Trek AI about this page

    HCPCS J9357: Valrubicin Injection, Intravesical 200 mg

    HCPCS Level II code J9357 describes an intravesical injection of valrubicin, 200 mg, used as an intravesical chemotherapy instillation procedure for treatment of bladder conditions; service type is intravesical chemotherapy administration and the typical site of service is outpatient hospital infusion center or urology clinic procedural suite.

    For related coverage guidance, see recent payer policy updates: Bendamustine Products Coverage Criteria, T-Cell Lymphoma Agents: Beleodaq, Istodax, Lymphir, Poteligeo, and Romidepsin, Brentuximab Vedotin (Adcetris®) Coverage Criteria.

    Customize your policy alerts

    Sign up for hcpcs J9357 policy alerts

    Get alerted when payer policies referencing J9357 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 7

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A typical patient is an adult with non‑muscle invasive bladder cancer (NMIBC) who has undergone transurethral resection of bladder tumor (TURBT) and is scheduled for intravesical chemotherapy with valrubicin. The patient presents to the urology clinic or ambulatory infusion suite on the day of treatment. A nurse confirms the treatment order for J9357 (valrubicin, intravesical, 200 mg), verifies allergies and recent urine cytology, and documents baseline vital signs. The urologist or qualified advanced practice provider performs bladder catheterization, instills the 200 mg valrubicin dose in preservative-free diluent, and instructs the patient to retain the instillate for the prescribed dwell time (commonly 1–2 hours) while remaining in the facility or at home per protocol. After dwell time, the nurse facilitates voiding or catheter-assisted drainage and disposes of waste per hazardous drug and biohazard regulations. Clinical documentation includes indication, dose, lot numbers, route intravesical, site of service (typically outpatient hospital department, ambulatory surgical center, or physician office), procedure start and stop times, patient tolerance, and any immediate adverse events. Billing uses HCPCS J9357 for the drug and may require additional CPT codes for catheterization or professional services as appropriate.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    51702Irrigation of bladder, simple, nonendoscopic, instillation of antineoplastic agentUsed when bladder instillation and dwell of antineoplastic agent are billed as the procedural service for intravesical therapy.
    51701Catheter insertion, indwelling (e.g., Foley), simple (separate procedure)Performed prior to instillation if a new catheter is placed for drug administration.
    51702Irrigation of bladder, simple, instillation of chemotherapeutic agentsDuplicate codes are not listed twice; see first 51702 row.
    51700Catheterization and drainage, each catheterization, simpleUsed when a single catheterization for drug instillation is performed and billed separately.
    51702(See above)Avoid duplicate listing; additional related codes may include facility or evaluation codes.

    If no CPT codes were provided in the input, the table above lists commonly associated codes used in the clinical workflow for intravesical chemotherapy. Each code should be reported per payer rules and documentation of catheterization, instillation, and time factors.

    Related Modifiers

    5 rows

    ModifierDescriptionWhen to Use
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    53Modifier 53 (Discontinued Procedure) signals that a surgical or diagnostic service was begun by the physician but terminated because of extenuating circumstances that threatened the patient’s…- Use modifier -53 when a physician/qualified healthcare professional has started a surgical or diagnostic procedure (e.g., anesthesia administered, incision or scope insertion) and then discontinues…
    62Modifier 62 indicates that two surgeons function as co‑surgeons, each performing distinct parts of the same primary surgical procedure. It is appended to the primary procedure code (and any…- Use modifier -62 when two surgeons act as co‑surgeons (both primary surgeons) on a single definitive primary procedure, each performing distinct parts of the same surgical procedure (append -62 to…
    78CPT modifier -78 indicates an unplanned, related return to the operating or procedure room by the same provider during the global postoperative period. It is appended when treatment for a…- Use modifier -78 when an unplanned, related complication during the original procedure’s global postoperative period requires the patient to return to a formal operating or procedure room and the…
    80CPT® Modifier 80 (Assistant Surgeon) is appended to a surgical CPT code when a physician (MD or DO) provides full, continuous assistance throughout the operative procedure. It is intended only for…- Use CPT Modifier -80 when a physician (MD or DO) serves as an assistant surgeon and provides full, continuous assistance throughout the entire operative procedure; append -80 to the surgical CPT…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    208800000X
    363L00000X
    207Q00000X
    363A00000X
    163WA0400X
    261QM0850X
    2085N0904X
    207PH0002X

    Related ICD-10-CM Codes

    29 rows

    ICD-10-CM CodeDescription
    C67.0Malignant neoplasm of trigone of bladder
    C67.1Malignant neoplasm of dome of bladder
    C67.2Malignant neoplasm of lateral wall of bladder
    C67.3Malignant neoplasm of anterior wall of bladder
    C67.4Malignant neoplasm of posterior wall of bladder
    C67.5Malignant neoplasm of bladder neck
    C67.6Malignant neoplasm of ureteric orifice
    C67.7Malignant neoplasm of urachus
    C67.8Malignant neoplasm of overlapping sites of bladder
    C67.9Malignant neoplasm of bladder, unspecified

    Showing 1–10 of 29

    Related Payer Policy Updates

    Specialty: Hematology/Oncology1 / 3

    10 rows

    PolicyPayerEffective Date
    Bendamustine Products Coverage Criteriablue cross blue shield - tennessee2027-01-30
    T-Cell Lymphoma Agents: Beleodaq, Istodax, Lymphir, Poteligeo, and RomidepsinMass General Brigham Health Plan2027-01-04
    Brentuximab Vedotin (Adcetris®) Coverage Criteriablue cross blue shield - tennessee2026-12-31
    Pemetrexed Coverageblue cross blue shield - tennessee2026-12-31
    Tumor Treatment Fields - Medical PolicyHealth-New-England2026-12-01
    Extracorporeal PhotopheresisCigna2026-11-15
    Hematology - AphexdaCigna2026-11-15
    VonvendiCigna2026-11-15
    Extracorporeal PhotopheresisCigna2026-11-15
    Yartemlea (narsoplimab-wuug) Coverage for TA-TMANeighborhood Health Plan of Rhode Island2026-11-01

    Related Codes

    HCPCS-J9000-DOXORUBICIN-10MG-INJECTION

    HCPCS J9000: Doxorubicin Hydrochloride Injection, 10 mg

    HCPCS-J9003-LEUPROLIDE-INJECTABLE-CAMCEVI-1MG

    HCPCS Level II J9003: Leuprolide injectable (camcevi etm), 1 mg

    HCPCS-J9010-ALEMTUZUMAB-INJECTION-10MG

    HCPCS Level II J9010: Injection, alemtuzumab, 10 mg

    HCPCS-J9011-DATOPOTAMAB-DERUXTECAN-INJECTION-1MG

    HCPCS J9011: Datopotamab Deruxtecan Injection, 1 mg

    HCPCS-J9015-ALDESLEUKIN-INJECTION-SINGLE-USE-VIAL

    HCPCS Level II J9015: Aldesleukin Injection, Single-Use Vial

    HCPCS-J9017-ARSENIC-TRIOXIDE-INJECTION-1MG

    HCPCS J9017: Arsenic Trioxide Injection, 1 mg

    HCPCS-J9019-ASPARAGINASE-ERWINAZE-INJECTION-1000-IU

    HCPCS Level II J9019: Asparaginase (Erwinaze) Injection, 1,000 IU

    HCPCS-J9020-ASPARAGINASE-INJECTION-10000-UNITS

    HCPCS J9020: Asparaginase Injection, 10,000 Units

    HCPCS-J9021-ASPARAGINASE-RYLAZE-INJECTION-0-1-MG

    HCPCS Level II J9021: Injection, asparaginase (Rylaze), 0.1 mg

    HCPCS-J9022-ATEZOLIZUMAB-INJECTION-10MG

    HCPCS J9022: Injection, atezolizumab 10 mg

    Showing 1–10 of 227

    • More pages

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.